Clinical trial
A Clinical Trial of Natalizumab in Individuals With Moderately to Severely…
NCT00078611 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00078611 |
|---|---|
| Title | A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease |
| Official title | A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous Antegren(TM) (Natalizumab) in Subjects With Moderately to Severely Active Crohn's Disease With Elevated C-Reactive Protein |
| Lead sponsor | Biogen, Industry |
| Collaborators | Elan Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | natalizumab |
| Enrollment | 462 |
| Start date | Mar 1, 2004 |
| Primary completion | Mar 1, 2005 |
| Completion | Mar 1, 2005 |
| First posted | Mar 8, 2004 |
| Last update posted | Jun 16, 2016 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: